Rights and permissions About this article Cite this article Scheen, A
If retatrutide is approved on schedule, somewhere around 2027 a doctor will be able to prescribe the real thing, manufactured to pharmaceutical standards, with a label that reflects whatever the cardiovascular data show and a titration plan supervised by someone who can order an ECG
Both sides of the litigation recently presented key scientific evidence during a science day session
Cardiovascular devices: 2 The impact on cardiology practice remains to be seen, although typically conservative approaches make it likely that stents, pacemakers, and other devices will continue to be widely used
Chao AM, Tronieri JS, Amaro A, et al
However, theyre not completely risk-free